Get the Stockscreener App
35.71
1.60%
-0.58
Mineralys Therapeutics Inc stock is traded at $35.71, with a volume of 900.84K.
It is down -1.60% in the last 24 hours and down -8.79% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$36.29
Open:
$36.24
24h Volume:
900.84K
Relative Volume:
0.62
Market Cap:
$2.83B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-13.08
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-3.85%
1M Performance:
-8.79%
6M Performance:
+149.72%
1Y Performance:
+191.51%
1-Day Range:
$35.66
$36.61
1-Week Range:
$35.01
$37.60
52-Week Range:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
35.71 | 2.87B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Nasdaq Moves: Is Mineralys Therapeutics Inc stock a safe investment in uncertain marketsJuly 2025 Outlook & Real-Time Volume Spike Alerts - moha.gov.vn
Behavioral Patterns of MLYS and Institutional Flows - Stock Traders Daily
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus - ts2.tech
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.4%What's Next? - MarketBeat
Oversold Conditions For Mineralys Therapeutics (MLYS) - Nasdaq
Simplify Asset Management Inc. Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Commit To Buy Mineralys Therapeutics At $22.50, Earn 16.1% Annualized Using Options - Nasdaq
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha
Swedbank AB Sells 84,500 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Earnings Notes - Trefis
Voya Investment Management LLC Grows Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge - Yahoo Finance
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears - Yahoo Finance
If These Biotech Stocks Pull Back, I'll Be Ready to Pull the Trigger - TheStreet Pro
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
(MLYS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Will Mineralys Therapeutics Inc. stock maintain dividend yieldTrade Entry Report & AI Enhanced Execution Alerts - Улправда
Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative? - Sahm
Analyst Upgrade: Can Mineralys Therapeutics Inc stock attract ESG capital inflowsEarnings Growth Summary & Weekly Stock Performance Updates - moha.gov.vn
Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
Is Mineralys Therapeutics Inc. stock near bottom after decline2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data By Investing.com - Investing.com Nigeria
Stifel Maintains Mineralys Therapeutics (MLYS) Buy Recommendation - Nasdaq
Why Mineralys Therapeutics Inc. stock is in analyst buy zone2025 Fundamental Recap & Fast Entry High Yield Stock Tips - Улправда
Mineralys stock price target raised to $52 by Stifel on strong trial data - Investing.com South Africa
Can Mineralys Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Momentum & Advanced Swing Trade Entry Plans - DonanımHaber
Is Mineralys Therapeutics Inc. stock ready for breakoutIPO Watch & Weekly Return Optimization Alerts - Улправда
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsWeekly Gains Summary & High Yield Equity Trading Tips - DonanımHaber
Is Mineralys Therapeutics Inc. stock a safe investment in uncertain marketsQuarterly Profit Summary & Daily Technical Stock Forecast Reports - DonanımHaber
JAMA Spotlights Mineralys Trial as Breakthrough for Resistant Hypertension - MyChesCo
Wall Street analysts think Mineralys Therapeutics, Inc. (MLYS) could surge 27.55%: Read this before placing a bet - MSN
Mineralys Therapeutics (MLYS): Reassessing Valuation After JAMA Spotlight on Lorundrostat’s Phase 3 Launch-HTN Trial - Sahm
Is Mineralys Therapeutics Inc a good long term investmentFinancial Sector Performance & Budget Friendly Trading Alerts - earlytimes.in
Did JAMA’s “Research of the Year” Nod for Launch-HTN Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative? - Sahm
Boothbay Fund Management LLC Sells 116,877 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Aug Opening: Is Mineralys Therapeutics Inc stock a contrarian buyPortfolio Performance Report & Daily Technical Stock Forecast Reports - moha.gov.vn
Biotech Shake-Up: New CEO Takes Helm at Jubilant Therapeutics - MyChesCo
Mineralys hypertension drug trial featured in JAMA’s top research of 2025 - Investing.com Canada
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) 'Research of the Year” Roundup - The Manila Times
Mineralys Therapeutics' Launch-HTN Trial Recognized by JAMA as One of 2025's Most Impactful Studies - Quiver Quantitative
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup - GlobeNewswire
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
73,921 Shares in Mineralys Therapeutics, Inc. $MLYS Acquired by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Price-Driven Insight from (MLYS) for Rule-Based Strategy - news.stocktradersdaily.com
Swiss National Bank Invests $838,000 in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
22NW LP Purchases 98,698 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Congleton Jon | Chief Executive Officer |
Nov 21 '25 |
Option Exercise |
0.54 |
24,082 |
13,004 |
655,387 |
| Slingsby Brian Taylor | Director |
Nov 20 '25 |
Sale |
43.35 |
1,000,000 |
43,350,000 |
7,903,838 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):